Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,569 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies.
Chang JY, Xu X, Shroff GS, Comeaux NI, Li W, Rodon Ahnert J, Karp DD, Dumbrava EE, Verma V, Chen A, Welsh J, Hong DS. Chang JY, et al. Among authors: welsh j. J Immunother Cancer. 2024 Oct 9;12(10):e009975. doi: 10.1136/jitc-2024-009975. J Immunother Cancer. 2024. PMID: 39384194 Free PMC article. Clinical Trial.
Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial.
Altan M, Wang Y, Song J, Welsh J, Tang C, Guha-Thakurta N, Blumenschein GR, Carter BW, Wefel JS, Ghia AJ, Yeboa DN, McAleer MF, Chung C, Woodhouse KD, McGovern SL, Wang C, Kim BYS, Weinberg JS, Briere TM, Elamin YY, Le X, Cascone T, Negrao MV, Skoulidis F, Ferrarotto R, Heymach JV, Li J. Altan M, et al. Among authors: welsh j. J Immunother Cancer. 2023 Jul;11(7):e006871. doi: 10.1136/jitc-2023-006871. J Immunother Cancer. 2023. PMID: 37402581 Free PMC article. Clinical Trial.
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.
Gregucci F, Spada S, Barcellos-Hoff MH, Bhardwaj N, Chan Wah Hak C, Fiorentino A, Guha C, Guzman ML, Harrington K, Herrera FG, Honeychurch J, Hong T, Iturri L, Jaffee E, Karam SD, Knott SRV, Koumenis C, Lyden D, Marciscano AE, Melcher A, Mondini M, Mondino A, Morris ZS, Pitroda S, Quezada SA, Santambrogio L, Shiao S, Stagg J, Telarovic I, Timmerman R, Vozenin MC, Weichselbaum R, Welsh J, Wilkins A, Xu C, Zappasodi R, Zou W, Bobard A, Demaria S, Galluzzi L, Deutsch E, Formenti SC. Gregucci F, et al. Among authors: welsh j. Oncoimmunology. 2023 Jun 21;12(1):2222560. doi: 10.1080/2162402X.2023.2222560. eCollection 2023. Oncoimmunology. 2023. PMID: 37363104 Free PMC article. Review.
Enhanced tumor control and survival in preclinical models with adoptive cell therapy preceded by low-dose radiotherapy.
Puebla-Osorio N, Fowlkes NW, Barsoumian HB, Xega K, Srivastava G, Kettlun-Leyton C, Nizzero S, Voss T, Riad TS, Wong C, Huang A, Hu Y, Mitchell J, Kim M, Rafiq Z, He K, Sezen D, Hsu E, Masrorpour F, Maleki A, Leuschner C, Cortez MA, Oertle P, Loparic M, Plodinec M, Markman JL, Welsh JW. Puebla-Osorio N, et al. Among authors: welsh jw. Front Oncol. 2024 Oct 9;14:1407143. doi: 10.3389/fonc.2024.1407143. eCollection 2024. Front Oncol. 2024. PMID: 39445067 Free PMC article.
1,569 results